Catalyst Pharmaceutical Partners Inc

    [td_text_with_title custom_title=”Company description”]Catalyst Pharmaceutical Partners Inc. (Catalyst Pharmaceuticals Ticker: CPRX), is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases. Catalyst’s lead program, Firdapse®, is currently in the late stages of a pivotal phase III, global, multi-centered trial for the treatment of patients with Lambert – Eaton Myasthenic Syndrome (LEMS). LEMS is a rare autoimmune disorder with the primary symptoms of debilitating muscle weakness, where the immune system attacks the nerves that control the muscles.

    Catalyst Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette’s disorder. Catalyst’s lead candidate, Firdapse® for the treatment of LEMS, is currently undergoing testing in a global, multi-center, pivotal phase III study. Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115 by Catalyst) to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder, Tourette’s disorder, and movement disorders associated with the treatment of Parkinson’s Disease.[/td_text_with_title]

    Drugs

    Firdapse

    Firdapse® is amifampridine phosphate or 3,4-diaminopyridine phosphate (3,4-DAP). It has received an orphan drug designation in the U.S. and orphan medicinal product designation in the European Union for the treatment of Lambert-Eaton Myasthenic Syndrome ("LEMS"). LEMS is an autoimmune neuromuscular disease in which the release of acetylcholine is decreased at the neuromuscular junction, resulting in [...]
    0 comments
    [td_text_with_title custom_title=”Latest post”]

    Catalyst files Firdapse

    CORAL GABLES, Fla., July 22, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the initiation of a rolling submission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for Firdapse® […]

    0 comments
    [/td_text_with_title]